tyruko
sandoz gmbh - natalitsumabin - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
capecitabin fair-med 150 mg tabletti, kalvopäällysteinen
fair-med healthcare gmbh - capecitabinum - tabletti, kalvopäällysteinen - 150 mg - kapesitabiini
capecitabin fair-med 500 mg tabletti, kalvopäällysteinen
fair-med healthcare gmbh - capecitabinum - tabletti, kalvopäällysteinen - 500 mg - kapesitabiini
pamolhot-c 750 mg / 300 mg porejauhe
orifarm healthcare a/s - ascorbic acid, paracetamol - porejauhe - 750 mg / 300 mg - parasetamoli
bortezomib teva 3.5 mg injektiokuiva-aine, liuosta varten
teva b.v. - bortezomibum - injektiokuiva-aine, liuosta varten - 3.5 mg - bortetsomibi
bortezomib teva 2.5 mg injektiokuiva-aine, liuosta varten
teva b.v. - bortezomibum - injektiokuiva-aine, liuosta varten - 2.5 mg - bortetsomibi